ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*JBDM Ver 2.0.16 (1th of February 2022) - 2999001/03458473CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120220817W173deBibliographieenBibliographyfrBibliographieEP17725914.0201705152018121120200115enenen1616979120160516EP1619872420161114EP2022081720223320190327201913202204132022152021042020220817202233C07K 14/47 20060101AFI20200110BHEP C07K 16/28 20060101ALI20200110BHEP G01N 33/50 20060101ALI20200110BHEP C12N 5/0783 20100101ALI20200110BHEP C07K 14/4748 20130101 FI20170803BHEP C12N 5/0637 20130101 LI20170803BHEP A61P 35/00 20180101 LI20200327BHEP A61P 35/04 20180101 LI20200331BHEP A61P 37/04 20180101 LI20200331BHEP A61P 43/00 20180101 LI20200331BHEP deSELEKTIV DEREGULIERTE MARKERMOLEKÜLEN IN TUMOR-INFILTRIERENDEN REGULIERENDE T-ZELLENenMARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS.frMARQUEURS SÉLECTIVEMENT DEREGULÉS DANS LES CELLULES T RÉGULATRICES PRÉSENTES DANS LES INFILTRTIONS TUMORALES.WO-A2-2007/044756WO-A2-2007/044756WO-A2-2009/100035WO-A2-2009/100035FEHRENBACHER L. ET AL.: "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial", THE LANCET, vol. 387, no. 10030, 9 March 2016 (2016-03-09), pages 1837-1846, XP002796570,BHAIRAVABHOTLA R. ET AL: "Transcriptome profiling of human FoxP3+regulatory T cells", HUMAN IMMUNOLOGY, vol. 77, no. 2, 10 December 2015 (2015-12-10), pages 201-213, XP029421993,PLITAS G. ET AL: "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, vol. 76, no. 4 Supplement, 15 February 2016 (2016-02-15), page P4-04-11, XP055396219, USGUAY S. & AKOUM A.: "Stable inhibition of interleukin 1 receptor type II in Ishikawa cells augments secretion of matrix metalloproteinases: possible role in endometriosis pathophysiology", REPRODUCTION, vol. 134, no. 3, September 2007 (2007-09), pages 525-534, XP002796571,MAR A.C. ET AL.: "Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis", J. BIOL. CHEM., vol. 290, no. 36, 4 September 2015 (2015-09-04), pages 22212-22224, XP002796572,TOSOLINI M. ET AL.: "Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.", CANCER RES., vol. 71, no. 4, 8 February 2011 (2011-02-08), pages 1263-1271, XP002796573,MARABELLE A ET AL: "Depleting tumor-specific Tregs at a single site eradicates disseminated tumors", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 123, no. 6, 1 June 2013 (2013-06-01), pages 2447-2463, XP002759891, ISSN: 0021-9738, DOI: 10.1172/JCI64859 [retrieved on 2013-05-24]TAKEUCHI Y. ET AL: "Roles of regulatory T cells in cancer immunity", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 8, 9 May 2016 (2016-05-09), pages 401-409, XP055396222,SELBY M.J. ET AL: "Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells", CANCER IMMUNOLOGY RESEARCH, vol. 1, no. 1, 7 April 2013 (2013-04-07), pages 32-42, XP055100395, DOI: 10.1158/2MARABELLE A ET AL: "Depleting tumor-specific Tregs at a single site eradicates disseminated tumors", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 123, no. 6, 1 June 2013 (2013-06-01), pages 2447-2463, XP002759891, ISSN: 0021-9738, DOI: 10.1172/JCI64859 [retrieved on 2013-05-24] cited in the applicationG PLITAS ET AL: "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, vol. 76, no. 4 Supplement, 15 February 2016 (2016-02-15), pages P4-04-11-P4-04-11, XP055396219, & 103RD ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; CHICAGO, IL, USA; MARCH 31 -APRIL 04, 2012 ISSN: 0008-5472, DOI: 10.1158/1538-7445.SABCS15-P4-04-11YOSHIKO TAKEUCHI ET AL: "Roles of regulatory T cells in cancer immunity", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 8, 9 May 2016 (2016-05-09), pages 401-409, XP055396222, ISSN: 0953-8178, DOI: 10.1093/intimm/dxw025BHAIRAVABHOTLA RAVIKIRAN ET AL: "Transcriptome profiling of human FoxP3+regulatory T cells", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 77, no. 2, 10 December 2015 (2015-12-10), pages 201-213, XP029421993, ISSN: 0198-8859, DOI: 10.1016/J.HUMIMM.2015.12.004PLITAS GEORGE ET AL: "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", IMMUNITY, vol. 45, no. 5, 15 November 2016 (2016-11-15), pages 1122-1134, XP029809259, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2016.10.032DE SIMONE MARCO ET AL: "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", IMMUNITY, vol. 45, no. 5, 15 November 2016 (2016-11-15), pages 1135-1147, XP029809250, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2016.10.021BHAIRAVABHOTLA R. ET AL: "Transcriptome profiling of human FoxP3+regulatory T cells", HUMAN IMMUNOLOGY, vol. 77, no. 2, 10 December 2015 (2015-12-10), pages 201-213, XP029421993,FEHRENBACHER L. ET AL.: "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial", THE LANCET, vol. 387, no. 10030, 9 March 2016 (2016-03-09), pages 1837-1846, XP002796570,SELBY M.J. ET AL: "Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells", CANCER IMMUNOLOGY RESEARCH, vol. 1, no. 1, 7 April 2013 (2013-04-07), pages 32-42, XP055100395, DOI: 10.1158/2TAKEUCHI Y. ET AL: "Roles of regulatory T cells in cancer immunity", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 8, 9 May 2016 (2016-05-09), pages 401-409, XP055396222,MARABELLE A ET AL: "Depleting tumor-specific Tregs at a single site eradicates disseminated tumors", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 123, no. 6, 1 June 2013 (2013-06-01), pages 2447-2463, XP002759891, ISSN: 0021-9738, DOI: 10.1172/JCI64859 [retrieved on 2013-05-24]MAR A.C. ET AL.: "Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis", J. BIOL. CHEM., vol. 290, no. 36, 4 September 2015 (2015-09-04), pages 22212-22224, XP002796572,GUAY S. & AKOUM A.: "Stable inhibition of interleukin 1 receptor type II in Ishikawa cells augments secretion of matrix metalloproteinases: possible role in endometriosis pathophysiology", REPRODUCTION, vol. 134, no. 3, September 2007 (2007-09), pages 525-534, XP002796571,PLITAS G. ET AL: "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, vol. 76, no. 4 Supplement, 15 February 2016 (2016-02-15), page P4-04-11, XP055396219, USTOSOLINI M. ET AL.: "Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.", CANCER RES., vol. 71, no. 4, 8 February 2011 (2011-02-08), pages 1263-1271, XP002796573,DE SIMONE MARCO ET AL: "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", IMMUNITY, CELL PRESS, AMSTERDAM, NL, vol. 45, no. 5, 15 November 2016 (2016-11-15), pages 1135-1147, XP029809250, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2016.10.02122159825.320220302ABRIGNANI, Sergiovia Rinascente 253040 Rapolano Terme (SI)ITPAGANI, MassimilianoPiazza Salvo d'Acquisto 4024069 Trescore Balneario (BG)ITCHECKMAB S.R.L.101762761P268353EPViale Luigi Majno, 2620129 MilanoITHGF101859891HGF Limited 1 City WalkLeeds LS11 9DXGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTREP201706164220170515enWO201719863120171123201747